ammonium hydroxide has been researched along with Migraine Disorders in 5 studies
azane : Saturated acyclic nitrogen hydrides having the general formula NnHn+2.
Migraine Disorders: A class of disabling primary headache disorders, characterized by recurrent unilateral pulsatile headaches. The two major subtypes are common migraine (without aura) and classic migraine (with aura or neurological symptoms). (International Classification of Headache Disorders, 2nd ed. Cephalalgia 2004: suppl 1)
| Excerpt | Relevance | Reference |
|---|---|---|
| "Although patients diagnosed as having migraine, have been studied extensively, there is no definite proof of a primary biochemical abnormality which is of significance in the pathogenesis of migraine." | 1.26 | Further observation on the possible relationship between migraine and serum ammonia levels. ( Bruyn, GW; de Bruijn, JG; Klawans, HL, 1976) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 4 (80.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (20.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Stankewitz, A | 1 |
| Voit, HL | 1 |
| Bingel, U | 1 |
| Peschke, C | 1 |
| May, A | 1 |
| Rivas Nuñez, CJ | 1 |
| Fernandez Martin, F | 1 |
| de Bruijn, JG | 1 |
| Bruyn, GW | 1 |
| Klawans, HL | 1 |
| Gilchrist, JM | 1 |
| Coleman, RA | 1 |
| Szám, I | 1 |
| Eckhardt, S | 1 |
| Németh, O | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Use of the Tx360 Nasal Applicator for Transnasal Sphenopalatine Ganglion Block in the Treatment of Chronic Migraine: A Double-blind Placebo-controlled Study[NCT01709708] | Phase 4 | 41 participants (Actual) | Interventional | 2012-09-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Number of acute medications used during Treatment period (6 weeks) and Follow-Up (4 weeks) (Group A vs. Group B). (NCT01709708)
Timeframe: 10 Weeks
| Intervention | Number of medications used (Mean) |
|---|---|
| Marcaine | 29.3 |
| Saline | 47.4 |
Number of adverse events over the entire length of study (Group A vs. Group B). (NCT01709708)
Timeframe: 34 weeks
| Intervention | Number of Adverse Events (Mean) |
|---|---|
| Marcaine | 7.67 |
| Saline | 5.29 |
Compare percentage change in Numeric Rating Scale (NRS) score from Before Procedure to 15-Minutes, Before Procedure to 30-Minutes, Before Procedure to 24-Hours After Procedure for all 12 treatments (Mean of all 12 treatments for each timepoint, comparing Group A to Group B). NRS is a likert scale ranging from 0-10 with 0 being no pain and 10 being worst possible pain. (NCT01709708)
Timeframe: 15 Minutes Post Treatment, 30 minutes Post Treatment and 24 hours Post Treatment, assessed up to 6 weeks
| Intervention | percentage of change (Mean) | ||
|---|---|---|---|
| 15 Minutes Post Treatment | 30 Minutes Post Treatment | 24 Hours Post Treatment | |
| Marcaine | -23.3 | -27.7 | -15.5 |
| Saline | -4.31 | -5.41 | 13.5 |
"Total Headache Impact Test (HIT-6) scores Pre-Treatment at Visit 2 vs. Post-Treatment (following final treatment), and at 1-Month Post-Treatment (Group A vs. Group B). HIT-6 is a series of 6 likert scale questions ranging from 1 to 5 with 1 being never and 5 being always. The HIT-6 answer options are weighted as follows: Never (1) = 6 points each, Rarely (2) = 9 points each, Sometimes (3) = 10 points each, Very often (4) = 11 points each, Always (5) = 13 points each. The total score for the HIT-6 ranges from 36 (subject answers all 6 questions as Never) to 78 subject answers all 6 questions as Always), with higher total scores indicating more impact than lower scores, i.e., headaches cause greater impact on the subject's life." (NCT01709708)
Timeframe: 10 Weeks
| Intervention | units on a scale (Mean) | ||
|---|---|---|---|
| Pre-Treatment | Post-Treatment | 1-Month Post-Treatment | |
| Marcaine | 64.36 | 59.85 | 59.23 |
| Saline | 64 | 62.5 | 61.92 |
Compare change in the number of migraine headache days per month reported in Baseline Period Diary vs. Treatment Period Diary vs. Post-Treatment Period Diary. (NCT01709708)
Timeframe: 12 Weeks
| Intervention | Migraine headache days per month (Mean) | ||
|---|---|---|---|
| Baseline | Treatment | Post Treatment | |
| Marcaine | 15.0 | 12.3 | 10.8 |
| Saline | 15.8 | 12.2 | 11.3 |
Compare Modified Pain Characteristic Questionnaire scores Before Procedure vs. 24-Hour After Procedure, Before Procedure vs. 1-Month Follow Up, and Before Procedure vs. 6-Month Follow Up (Mean of all 12 treatments for each timepoint, comparing Group A to Group B). The modified pain characteristic questionnaire is a series of 11 questions on a likert scale ranging from 0 to 10 with 0 being no pain or does not interfere and 10 being worst pain or completely interferes. Percentage questions range from 0 to 100. (NCT01709708)
Timeframe: Before Treatment, 24 Hours After Treatment, 1 Month Post Treatment, and 6 Months Post Treatment
| Intervention | units on a scale (Mean) | |||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Worst Pain Question: Before Treatment | Worst Pain Question: 24 Hours After Treatment | Worst Pain Question: 1 Month Post Treatment | Worst Pain Question: 6 Months Post Treatment | Least Pain Question: Before Treatment | Least Pain Question: 24 Hours After Treatment | Least Pain Question: 1 Month Post Treatment | Least Pain Question: 6 Months Post Treatment | Average Pain Question: Before Treatment | Average Pain Question: 24 Hours After Treatment | Average Pain Question: 1 Month Post Treatment | Average Pain Question: 6 Months Post Treatment | Percent Relief Question: Before Treatment | Percent Relief Question: 24 Hours After Treatment | Percent Relief Question: 1 Month Post Treatment | Percent Relief Question: 6 Months Post Treatment | General Activity Question: Before Treatment | General Activity Question: 24 Hours After Treatmen | General Activity Question: 1 Month Post Treatment | General Activity Question: 6 Months Post Treatment | Mood Interference Question: Before Treatment | Mood Interference Question: 24 Hours After Treatme | Mood Interference Question: 1 Month Post Treatment | Mood Interference Question: 6 Months Post Treatmen | Walking Ability Question: Before Treatment | Walking Ability Question: 24 Hours After Treatment | Walking Ability Question: 1 Month Post Treatment | Walking Ability Question: 6 Months Post Treatment | Normal Work Question: Before Treatment | Normal Work Question: 24 Hours After Treatment | Normal Work Question: 1 Month Post Treatment | Normal Work Question: 6 Months Post Treatment | Relationships Question: Before Treatment | Relationships Question: 24 Hours After Treatment | Relationships Question: 1 Month Post Treatment | Relationships Question: 6 Months Post Treatment | Sleep Interference Question: Before Treatment | Sleep Interfere Question: 24 Hours After Treatment | Sleep Interferenc Question: 1 Month Post Treatment | Sleep Interference Question: 6 Months Post Treatme | Enjoyment Question: Before Treatment | Enjoyment Question: 24 Hours After Treatment | Enjoyment Question: 1 Month Post Treatment | Enjoyment Question: 6 Months Post Treatment | |
| Marcaine | 4.75 | 4.36 | 4.56 | 4.27 | 2.01 | 1.77 | 1.88 | 1.68 | 3.39 | 3.07 | 3.36 | 2.86 | 41.3 | 46.0 | 46.3 | 34.7 | 2.49 | 2.31 | 2.64 | 2.68 | 2.57 | 2.42 | 2.96 | 3.18 | 0.63 | 0.54 | 0.80 | 0.45 | 2.53 | 2.21 | 2.52 | 2.59 | 2.00 | 1.96 | 2.36 | 2.05 | 2.29 | 1.89 | 1.92 | 1.55 | 2.81 | 2.58 | 2.64 | 3.18 |
| Saline | 6.15 | 6.16 | 5.64 | 5.88 | 2.50 | 2.43 | 2.64 | 2.88 | 4.33 | 4.27 | 3.91 | 4.00 | 29.2 | 29.8 | 21.0 | 18.6 | 3.50 | 3.64 | 3.91 | 4.00 | 3.78 | 4.19 | 3.82 | 5.71 | 1.27 | 1.24 | 0.55 | 0.43 | 3.49 | 3.63 | 3.45 | 3.71 | 3.47 | 3.90 | 3.09 | 3.86 | 2.68 | 2.85 | 2.55 | 3.14 | 3.12 | 3.34 | 3.09 | 4.00 |
Compare Numeric Rating Scale (NRS) scores Before Procedure,15-Minute Post Treatment, 30-Minutes Post Treatment, 24-Hour Post Treatment for all 12 treatments (Marcaine vs. Saline). NRS is a likert scale ranging from 0-10 with 0 being no pain and 10 being worst possible pain. For each individual time point, all 12 treatments were averaged for that time point and a single value was used for comparison between the two groups. (NCT01709708)
Timeframe: 6 Weeks
| Intervention | units on a scale (Mean) | |||
|---|---|---|---|---|
| Before Procedure | 15 Minutes Post Treatment | 30 Minutes Post Treatment | 24 Hours Post Treatment | |
| Marcaine | 3.18 | 2.53 | 2.41 | 2.85 |
| Saline | 3.78 | 3.51 | 3.45 | 4.20 |
Satisfaction scores Visit 2 vs. following treatment (Treatment 12) and at 1-Month Post-Treatment (Group A vs. Group B). Satisfaction scores are a likert scale ranging from 1 to 5 with 1 being complete dissatisfaction and 5 being complete satisfaction. (NCT01709708)
Timeframe: 10 Weeks
| Intervention | units on a scale (Mean) | ||
|---|---|---|---|
| Visit 2 | Following treatment (Treatment 12) | 1-Month Post-Treatment | |
| Marcaine | 3.52 | 3.55 | 3.57 |
| Saline | 3.00 | 2.50 | 2.64 |
Compare 24-Hour After Procedure Patient's Global Impression of Change (PGIC) score for 12 treatments (Mean of all 12 treatments for each timepoint, comparing Group A to Group B). PGIC is a likert scale ranging from 1 to 7 with 1 being very much improved and 7 being very much worse. (NCT01709708)
Timeframe: 30 minutes Post Treatment and 24 hours Post Treatment, assessed up to 6 weeks
| Intervention | units on a scale (Mean) | |
|---|---|---|
| 30 Minutes Post Treatment | 24 Hours Post Treatment | |
| Marcaine | 3.00 | 3.08 |
| Saline | 3.72 | 3.88 |
1 review available for ammonium hydroxide and Migraine Disorders
| Article | Year |
|---|---|
[Biochemical aspects of migraine].
Topics: 5-Hydroxytryptophan; Age Factors; Ammonia; Blood Platelet Disorders; Female; Humans; Menstruation; M | 1975 |
4 other studies available for ammonium hydroxide and Migraine Disorders
| Article | Year |
|---|---|
A new trigemino-nociceptive stimulation model for event-related fMRI.
Topics: Adult; Ammonia; Brain Stem; Female; Humans; Irritants; Magnetic Resonance Imaging; Male; Migraine Di | 2010 |
Further observation on the possible relationship between migraine and serum ammonia levels.
Topics: Adult; Ammonia; Humans; Migraine Disorders | 1976 |
Ornithine transcarbamylase deficiency: adult onset of severe symptoms.
Topics: Adult; Ammonia; Brain Diseases, Metabolic; Female; Hemiplegia; Heterozygote; Humans; Mental Disorder | 1987 |
[Further studies on clopamide].
Topics: Adult; Amides; Ammonia; Clopamide; Diuretics; Female; Humans; Hypertension; Lymphedema; Male; Middle | 1970 |